Vikram Atit, MD
Neurology · Holiday, FLNPI 1871560904
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.4%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by AbbVie at 36.1% of the total. Reporting peaked in 2021 at $19,870 and has fallen 81.3% since, to $3,707 in 2025. Among neurology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,053 payments — averaging $31.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$24K
- Sunovion Pharmaceuticals Inc.$4K
- SK Life Science, Inc.$4K
- Biohaven Pharmaceutical Holding Company Ltd.$3K
- UCB, Inc.$2K
- Novartis$2K
- plus $27K from 54 others
Across 45 payments — averaging $72,708 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$3.2M
- Novo Nordisk AS$26K
What the payments were for
- Consulting fees$2,6254%
- Speaking & faculty fees$23,57036%
- Travel & lodging$1,3382%
- Food & beverage$37,38957%
- Education$2680%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$65,191 in reported general payments places this provider in the 90th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 40 | $450,148 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 14 | $335,352 |
| IngrezzaValbenazine Tosylate | 21 | $172,201 |
| TysabriNatalizumab | 12 | $97,929 |
| AptiomEslicarbazepine Acetate | 49 | $75,335 |
| UbrelvyUbrogepant | 20 | $29,741 |
| QuliptaAtogepant | 19 | $23,841 |
| Nurtec OdtRimegepant Sulfate | 11 | $22,932 |
| XareltoRivaroxaban | 34 | $21,796 |
| RytaryCarbidopa/Levodopa | 15 | $7,985 |
| BrilintaTicagrelor | 16 | $7,406 |
| Levetiracetam ErLevetiracetam | 14 | $3,186 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 94 | $2,945 |
| Oxcarbazepine | 44 | $2,310 |
| Memantine Hcl | 86 | $1,858 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $157 | $335,35214 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $2,010 | $172,20121 claims |
| BiogenTysabri | $832 | $97,92912 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $3,831 | $75,33549 claims |
| AbbVieUbrelvy, Qulipta | $23,557 | $53,58239 claims |
| PfizerNurtec Odt | $811 | $22,93211 claims |
| Johnson & JohnsonXarelto | $787 | $21,79634 claims |
| Amneal Pharmaceuticals LLCRytary | $919 | $7,98515 claims |
| AstraZenecaBrilinta | $1,383 | $7,40616 claims |
| Upsher-smith Laboratories LLCTopiramate | $159 | $24541 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,434 neurology providers in Florida.
Other neurology in Holiday
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
- Donald NegroskiSarasota$1.4M
- Mark CascioneTampa$1.2M
- Lance KimOcala$1M
- Tuan VuTampa$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.